Abstract:<p class="a-plus-plus">Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several precipitating factors by chemical exposure and skin injury present commonly in patients with vitiligo. Although the diagnosis appears to be straightforward for the distinct clinical phenotype and specific histological features, vitiligo provides many challenges including chronicity, treatment resistance, frequent relapse, associated profound psychosocial effect, and negative impact on quality of life. Multiple mechanisms are involved in melanocyte disappearance, including genetics, environmental factors, and immune-mediated inflammation. Compelling evidence supports the melanocyte intrinsic abnormalities with poor adaptation to stressors leading to instability and release of danger signals, which will activate dendritic cells, natural killer cells, and innate lymphoid cells to initiate innate immunity, ultimately resulting in T-cell mediated adaptive immune response and melanocyte destruction. Importantly, the cross- talk between keratinocytes, melanocytes, and immune cells, such as interferon (IFN)-γ signaling pathway, builds inflammatory loops that give rise to the disease deterioration. Improved understanding of the immune pathogenesis of vitiligo has led to the development of new therapeutic options including Janus kinase (JAK) inhibitors targeting IFN-γ signaling pathways, which can effectively reverse depigmentation. Furthermore, definition of treatment goals and integration of comorbid diseases into vitiligo management have revolutionized the way vitiligo is treated. In this review, we highlight recent developments in vitiligo clinical aspects and immune pathogenesis. Our key objective is to raise awareness of the complexity of this disease, the potential of prospective therapy strategies, and the need for early and comprehensive management.</p>

Advances in the Treatment of Vitiligo on Special Sites

Vitiligo Treatment : A Review of Latest Treatment Researches

Vitiligo nonsurgical treatment: a review of latest treatment researches

Advances in vitiligo: Update on therapeutic targets

The Treatment of Vitiligo with Liver and Kidney Deficiencies

Research Progress on Targeted Antioxidant Therapy and Vitiligo

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Advances in the Research about Vitiligo Immunology

Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo

Vitiligo: Translational research and effective therapeutic strategies

The enigma and challenges of vitiligo pathophysiology and treatment

Management of the refractory vitiligo patient: current therapeutic strategies and future options

Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection

Emerging drugs for the treatment of vitiligo

Vitiligo: advances in pathophysiology research and treatment development

Current and emerging treatments for vitiligo

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Target area treatment ratio of varied lesions in the cultured pure melanocyte transplantation repigmentation of vitiligo: A retrospective study

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Updates and new medical treatments for vitiligo (Review)

An update on Vitiligo pathogenesis